Abstract
Thrombopoietin (TPO) is a critical regulator of hematopoiesis. We previously reported that a severe aplastic anemia (SAA) who received a short-term administration of pegylated recombinant human megakaryocyte growth and development factor (rHuMGDF). A trilineage hematologic response was induced, however the patient was diagnosed with leukemia after nine years and eight months from administration of rHuMGDF. In recent reports, somatic mutations in myeloid cancer candidate genes were present in one-third of the AA. A mutant clone may be expanded by rHuMGDF in our patient. The long-term safety of patients treated with TPO and eltrombopag remains unknown. Careful observations are warranted hereafter.
Highlights
Com Introduction - Aplastic anemia (AA) is one of the lifen threatening bone-marrow failure syndromes o characterized by pancytopenia and N hypoplastic marrow
We report here the meaningful clinical course of a Japanese patient with severe aplastic anemia n (SAA), hematopoietic stem cell transplantation our hospital
The patient was readmitted to our hos- leukemia in a long-term observation after age and stage of severity
Summary
Com Introduction - Aplastic anemia (AA) is one of the lifen threatening bone-marrow failure syndromes o characterized by pancytopenia and N hypoplastic marrow. His bone marrow TPO was canceled principally because the short-term administration of rHuMGDF is (BM) showed hypocellularity with 23% production of the anti-TPO antibody in subsuspected of contributing to this clonal evo- blasts, which were peroxidase (+), CD13 jects received TPO. About 15% of lack HSCs. we thought that the hematopoiesis has received considerable AA patients have a risk of development of short-term administration of rHuMGDF attention adopt a perspective of clonal evo- MDS/AML.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
